🔎 Trials Near Me

Início › Doença de Crohn › Indiana

Ensaios clínicos de Doença de Crohn em Indiana

13 estudos para Doença de Crohn estão buscando participantes em locais em Indiana.

Cidades em Indiana

Texto oficial do estudo (Inglês)

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

  • Indiana University Health University Hospital ( Site 5022), Indianapolis
RecrutandoFase 3
Idades de 16 a 80 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06430801

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

  • Gastroenterology Health Partners /ID# 284145, New Albany
RecrutandoFase 2
Idades de 18 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT07697456

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  • Indiana University Health University Hospital /ID# 278129, Indianapolis
RecrutandoFase 2
Idades de 18 a 75 · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06548542

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  • IU Health University Hospital, Indianapolis
RecrutandoFase 2/3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07196722

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

  • Riley Hospital for Children, Indianapolis
RecrutandoFase 3
Idades 3 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06663332

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  • Indiana University Health University Hospital, Indianapolis
  • Gastroenterology Health Partners, New Albany
RecrutandoFase 3
Idades de 18 a 70 · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT06937099

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • Gastroenterology Health Partners, PLLC - New Albany-Site Number: 8400100, New Albany
RecrutandoFase 3
Idades de 16 a 80 · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT07184931

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • Gastroenterology Health Partners, PLLC - New Albany-Site Number: 8400100, New Albany
RecrutandoFase 3
Idades de 16 a 80 · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT07184944

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

  • Indiana University Health Riley Hospital for Children /ID# 256454, Indianapolis
RecrutandoFase 3
Idades de 2 a 17 · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT05995353

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

  • Riley Childrens Hospital, Indianapolis
RecrutandoFase 3
Idades de 2 a 17 · Todos os sexos · Atualizado em 24 de ago. de 2026 · NCT05509777

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

  • Indiana University Health Riley Hospital for Children /ID# 262215, Indianapolis
RecrutandoFase 3
Idades de 2 a 17 · Todos os sexos · Atualizado em 24 de jun. de 2026 · NCT06332534

Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

  • Riley Hospital for Children at Indiana University Health, Indianapolis
RecrutandoFase 4
Idades de 6 a 17 · Todos os sexos · Atualizado em 27 de mai. de 2026 · NCT05781152

Precise Infliximab Exposure and Pharmacodynamic Control

  • Riley Hospital for Children, Indianapolis
RecrutandoFase 2/3
Idades de 6 a 22 · Todos os sexos · Atualizado em 5 de mai. de 2026 · NCT05660746

Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.